419
Views
2
CrossRef citations to date
0
Altmetric
Research Article

Ethics of clinical research in patients with ALS: is there a risk of exploitation?

Pages 161-166 | Received 08 Mar 2017, Accepted 08 Aug 2017, Published online: 04 Sep 2017
 

Abstract

Amyotrophic lateral sclerosis is the most common degenerative disease of the motor neuron network. Due to its inevitably fatal outcome, numerous attempts have been made to ameliorate its course. The emergence of every new technology has spurred research to see if it might benefit patients with ALS (PALS). This paper suggests a detailed road map to be followed when performing clinical research in PALS to satisfy the ethics requirements of the Declaration of Helsinki, expressed using the terminology of Beauchamp and Childress. The ethics principles that need to be satisfied are arranged in a hierarchical manner, each having to be satisfied before the next is approached: Justice; Beneficence, Nonmaleficence, Professional-Patient Relationship, and Respect for Autonomy. Study participants’ autonomy can be respected only when all other principles have been addressed before PALS are approached to participate. Five ‘red flags’ are identified, which, if present, might indicate a risk that PALS may be exploited. PALS who are contemplating new treatments or clinical trials and their families will be assured that their best interests are the only ones that matter whenever adherence to established ethics principles and avoidance of known pitfalls are made explicit.

Acknowledgements

Presented in part at the WFN Satellite Symposium on Stem Cells in Dublin, December 6th, 2016. Based in part on responses to questions posed by four Tel Aviv University Sackler School of Medicine students whom I asked (November 27th 2016): “What questions do we need to answer, in order to address the ethics of stem cell research in PALS?”

Declaration of interest

None relevant to this presentation.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.